|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARFGAP2 |
Gene summary for ARFGAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARFGAP2 | Gene ID | 84364 |
| Gene name | ADP ribosylation factor GTPase activating protein 2 | |
| Gene Alias | IRZ | |
| Cytomap | 11p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | G5E9L0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84364 | ARFGAP2 | LZE4T | Human | Esophagus | ESCC | 2.78e-16 | 3.76e-01 | 0.0811 |
| 84364 | ARFGAP2 | LZE7T | Human | Esophagus | ESCC | 8.96e-08 | 5.22e-01 | 0.0667 |
| 84364 | ARFGAP2 | LZE8T | Human | Esophagus | ESCC | 4.61e-09 | 2.89e-01 | 0.067 |
| 84364 | ARFGAP2 | LZE20T | Human | Esophagus | ESCC | 4.78e-04 | 1.94e-01 | 0.0662 |
| 84364 | ARFGAP2 | LZE22T | Human | Esophagus | ESCC | 4.87e-03 | 2.65e-01 | 0.068 |
| 84364 | ARFGAP2 | LZE24T | Human | Esophagus | ESCC | 8.29e-18 | 3.75e-01 | 0.0596 |
| 84364 | ARFGAP2 | LZE6T | Human | Esophagus | ESCC | 1.73e-05 | 1.98e-01 | 0.0845 |
| 84364 | ARFGAP2 | P1T-E | Human | Esophagus | ESCC | 1.08e-02 | 2.50e-01 | 0.0875 |
| 84364 | ARFGAP2 | P2T-E | Human | Esophagus | ESCC | 2.80e-23 | 5.01e-01 | 0.1177 |
| 84364 | ARFGAP2 | P4T-E | Human | Esophagus | ESCC | 6.54e-11 | 2.60e-01 | 0.1323 |
| 84364 | ARFGAP2 | P5T-E | Human | Esophagus | ESCC | 8.20e-13 | 2.45e-01 | 0.1327 |
| 84364 | ARFGAP2 | P8T-E | Human | Esophagus | ESCC | 1.14e-18 | 3.61e-01 | 0.0889 |
| 84364 | ARFGAP2 | P9T-E | Human | Esophagus | ESCC | 9.81e-20 | 2.98e-01 | 0.1131 |
| 84364 | ARFGAP2 | P10T-E | Human | Esophagus | ESCC | 1.19e-18 | 3.79e-01 | 0.116 |
| 84364 | ARFGAP2 | P11T-E | Human | Esophagus | ESCC | 2.39e-20 | 8.14e-01 | 0.1426 |
| 84364 | ARFGAP2 | P12T-E | Human | Esophagus | ESCC | 3.49e-16 | 4.00e-01 | 0.1122 |
| 84364 | ARFGAP2 | P15T-E | Human | Esophagus | ESCC | 1.08e-24 | 5.68e-01 | 0.1149 |
| 84364 | ARFGAP2 | P16T-E | Human | Esophagus | ESCC | 2.01e-24 | 4.62e-01 | 0.1153 |
| 84364 | ARFGAP2 | P17T-E | Human | Esophagus | ESCC | 6.10e-11 | 3.98e-01 | 0.1278 |
| 84364 | ARFGAP2 | P19T-E | Human | Esophagus | ESCC | 1.07e-10 | 5.51e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:001605014 | Esophagus | ESCC | vesicle organization | 211/8552 | 300/18723 | 2.85e-18 | 2.87e-16 | 211 |
| GO:0006900111 | Esophagus | ESCC | vesicle budding from membrane | 54/8552 | 61/18723 | 2.66e-12 | 1.07e-10 | 54 |
| GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
| GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
| GO:00069038 | Esophagus | ESCC | vesicle targeting | 38/8552 | 45/18723 | 8.42e-08 | 1.43e-06 | 38 |
| GO:004819914 | Esophagus | ESCC | vesicle targeting, to, from or within Golgi | 19/8552 | 21/18723 | 2.28e-05 | 1.96e-04 | 19 |
| GO:000690115 | Esophagus | ESCC | vesicle coating | 16/8552 | 17/18723 | 3.46e-05 | 2.82e-04 | 16 |
| GO:00481947 | Esophagus | ESCC | Golgi vesicle budding | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:004819311 | Liver | Cirrhotic | Golgi vesicle transport | 153/4634 | 296/18723 | 1.02e-23 | 6.43e-21 | 153 |
| GO:001605011 | Liver | Cirrhotic | vesicle organization | 133/4634 | 300/18723 | 7.35e-14 | 6.41e-12 | 133 |
| GO:000690012 | Liver | Cirrhotic | vesicle budding from membrane | 41/4634 | 61/18723 | 3.12e-12 | 2.25e-10 | 41 |
| GO:0048199 | Liver | Cirrhotic | vesicle targeting, to, from or within Golgi | 15/4634 | 21/18723 | 8.85e-06 | 1.30e-04 | 15 |
| GO:00069013 | Liver | Cirrhotic | vesicle coating | 13/4634 | 17/18723 | 1.09e-05 | 1.56e-04 | 13 |
| GO:005165611 | Liver | Cirrhotic | establishment of organelle localization | 128/4634 | 390/18723 | 1.78e-04 | 1.67e-03 | 128 |
| GO:00069034 | Liver | Cirrhotic | vesicle targeting | 22/4634 | 45/18723 | 3.90e-04 | 3.23e-03 | 22 |
| GO:005165011 | Liver | Cirrhotic | establishment of vesicle localization | 58/4634 | 161/18723 | 8.98e-04 | 6.44e-03 | 58 |
| GO:005164811 | Liver | Cirrhotic | vesicle localization | 62/4634 | 177/18723 | 1.37e-03 | 9.18e-03 | 62 |
| GO:00481943 | Liver | Cirrhotic | Golgi vesicle budding | 7/4634 | 10/18723 | 3.29e-03 | 1.83e-02 | 7 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARFGAP2 | SNV | Missense_Mutation | novel | c.101C>A | p.Pro34Gln | p.P34Q | Q8N6H7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| ARFGAP2 | SNV | Missense_Mutation | c.23N>T | p.Thr8Ile | p.T8I | Q8N6H7 | protein_coding | tolerated(0.05) | benign(0.172) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ARFGAP2 | insertion | Frame_Shift_Ins | novel | c.210_211insTTCTTGAGAATCACCCGTAGCACGCGCTG | p.Asn71PhefsTer10 | p.N71Ffs*10 | Q8N6H7 | protein_coding | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ARFGAP2 | SNV | Missense_Mutation | novel | c.869A>C | p.Lys290Thr | p.K290T | Q8N6H7 | protein_coding | deleterious(0.05) | probably_damaging(0.987) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ARFGAP2 | SNV | Missense_Mutation | c.1417N>T | p.His473Tyr | p.H473Y | Q8N6H7 | protein_coding | tolerated(0.06) | benign(0.027) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ARFGAP2 | SNV | Missense_Mutation | rs372871965 | c.566C>T | p.Pro189Leu | p.P189L | Q8N6H7 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ARFGAP2 | SNV | Missense_Mutation | c.648G>T | p.Lys216Asn | p.K216N | Q8N6H7 | protein_coding | deleterious(0) | possibly_damaging(0.649) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| ARFGAP2 | SNV | Missense_Mutation | novel | c.1517N>C | p.Leu506Pro | p.L506P | Q8N6H7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARFGAP2 | SNV | Missense_Mutation | rs760907325 | c.278N>A | p.Arg93His | p.R93H | Q8N6H7 | protein_coding | tolerated(0.73) | benign(0.017) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARFGAP2 | deletion | Frame_Shift_Del | rs772728725 | c.276delN | p.Arg93AlafsTer43 | p.R93Afs*43 | Q8N6H7 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |